WHO Guidelines for the Treatment of Leprosy
Drug Regimens for Paucibacillary (PB) and Multibacillary (MB) Leprosy
WHO's guidelines for leprosy treatment define drug regimens for paucibacillary (PB) and multibacillary (MB) cases, ensuring effective disease management.
WHO Guidelines for the Treatment of Leprosy
Understanding Leprosy Treatment
Leprosy, also known as Hansen's disease, is a chronic infectious disease caused by Mycobacterium leprae. Effective treatment involves multidrug therapy (MDT), classified into regimens for paucibacillary (PB) and multibacillary (MB) leprosy.
Drug Regimens for Paucibacillary (PB) Leprosy
PB leprosy cases require a combination of rifampicin and dapsone administered over six months.
Recommended Dosage
- Rifampicin: 600 mg once monthly
- Dapsone: 100 mg daily
Drug Regimens for Multibacillary (MB) Leprosy
MB leprosy cases require a combination of rifampicin, clofazimine, and dapsone administered over 12 months.
Recommended Dosage
- Rifampicin: 600 mg once monthly
- Clofazimine: 300 mg once monthly, 50 mg daily
- Dapsone: 100 mg daily
Importance of Adherence to MDT
Adherence to WHO guidelines ensures complete eradication of the infection, preventing disability and transmission. Early diagnosis and consistent treatment significantly improve patient outcomes.
Tags
Recommended Reads
Explore related articles that might interest you
WHO Guidelines for the Treatment of Leprosy
WHO Guidelines for the Treatment of Leprosy
Pharmacology, administration, and adverse effects of pharmacotherapies for different classes of leprosy based on national guidelines
Pharmacology of antileprotic drugs: Mechanisms of action, classifications, dosage regimens, adverse effects, therapeutic indications, and contraindications
Pharmacology, administration, and adverse effects of pharmacotherapies for different classes of leprosy based on national guidelines
WHO Guidelines for the Treatment of Leprosy
